Compare Novo Nordisk A/S (NVO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Uranium Energy Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Novo Nordisk A/S is far larger — about 36.5× Uranium Energy Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Uranium Energy Corp for 37 Days on average.
| NVO | UEC | |
|---|---|---|
Market Cap | $165.31B | $4.53B |
Volume | 11,432,838 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $63.98 | $20.14 |
52-Week Low | $35.29 | $9.04 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $179.56B | $4.03B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Uranium Energy (UEC) trades at $9.14, down 3.48% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M but a net loss of $137M, reflecting operational challenges. Recent news highlights production expansion at two U.S. mines and unhedged sales strategy delivering $93.13 per pound realized price. Cash flow remains negative from operations but positive overall due to significant financing activities.
UEC faces fundamental headwinds with negative profitability metrics and high valuation ratios, though Wall Street maintains bullish sentiment with 87.5% buy ratings and $16.06 consensus price target. Key risks include production sustainability questions and dependence on uranium price volatility. The stock offers speculative upside if operational improvements materialize amid growing nuclear energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
